MMI Secures $125M Series D to Expand Robotic Microsurgery System
MMI raised $125 million in Series D funding to grow commercial reach of its Symani Surgical System and build clinical evidence for robotic microsurgery.
Medical Microinstruments (MMI) has closed a $125 million Series D funding round aimed at accelerating the worldwide commercial rollout of its Symani Surgical System, a robotic platform designed for microsurgery procedures, the company announced.
The capital infusion is intended to support three primary objectives: expanding into new markets, broadening patient access to the technology, and generating the clinical evidence necessary to establish a wider role for robotic assistance in microsurgical settings.
Read more Aetna Reports 69% of Medicare Advantage Members in Top-Rated Plans →
Robotic microsurgery represents a specialized and technically demanding segment of the surgical robotics market, with instruments engineered to operate at a scale far smaller than conventional robotic surgical systems. MMI's Symani platform targets procedures that require extreme precision, such as reconstructive and lymphatic surgeries.
The Series D round signals continued investor confidence in the surgical robotics sector, where competition and capital deployment have intensified as device makers race to demonstrate clinical outcomes and secure reimbursement pathways in key markets. Commercial expansion backed by robust clinical data is widely viewed as critical to long-term adoption of emerging robotic platforms.
Terms of the financing, including the identities of participating investors, were not disclosed in the announcement. Continue reading at GlobeNewswire - Mergers And Acquisitions.
